During the preclinical stage of drug development, timelines are critical for the filing of an Investigational New Drug (IND) application within a predetermined timeframe and budget. Evolving market pressures have changed the focus of the drug development industry, accelerating early phases further in order to create late-stage pipeline growth. Given these increasing pressures, understanding how and when to plan your preclinical IND-enabling program is an integral part of meeting specific milestones leading to on-time IND submission.
Learn through our years of IND research experience, unique range of services and best-in-class expertise how we are best suited to help you successfully initiate and complete your IND-enabling program. With our ongoing efforts to improve upon our internal processes and continued focus on scientific excellence and guidance, we are pleased to announce the most cost-effective IND program for our clients.
For your IND guide and full access to our accelerated reporting timelines, including a full-size Gantt chart, please log in to the Source℠. If you are not a member of the Source℠, our new online scientific and educational information center, please click here to register.
Related Information
Webinar Replay – Planning and Understanding Your IND Program (Available only in the Source℠)
For more information about how we can support your IND program, contact us at 1.877.CRIVER.1 (1.877.274.8371) or askcharlesriver@crl.com.